Dietary resveratrol does not delay engraftment, sensitize to vincristine or inhibit growth of high-risk acute lymphoblastic leukemia cells in NOD/SCID mice

Susan J. Zunino, David H. Storms, John W. Newman, Theresa L. Pedersen, Carl L Keen, Jonathan M Ducore

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Acute lymphoblastic leukemia (ALL) with translocation t(4;11) is a high-risk leukemia found in 60-85% of infants with ALL and is often refractory to conventional chemotherapeutics after relapse. To evaluate the efficacy of dietary resveratrol in vivo, 5-week-old NOD.CB17-Prkdcscid/J mice were fed a control diet or a diet containing 0.2% w/w resveratrol. After 3 weeks of dietary treatment, mice were engrafted with the human t(4;11) ALL line SEM by tail vein injection. Engraftment was monitored by evaluating the presence of human CD19+ cells in peripheral blood using flow cytometry. Relative to control diet, dietary resveratrol did not delay the engraftment of the leukemia cells. To determine if dietary resveratrol could increase efficacy of a chemotherapeutic agent, vincristine was injected intraperitoneally into leukemic mice fed the control or supplemented diet. Survival curves and monitoring the percentage of human leukemia cells in peripheral blood showed that resveratrol did not inhibit leukemia cell growth or influence the activity of vincristine. Mass spectrometric analysis of mouse serum revealed that the majority of resveratrol was present as glucuronidated and sulfated metabolites. These data do not support the concept that dietary resveratrol has potential as a preventative agent against the growth of high-risk t(4;11) ALL.

Original languageEnglish (US)
Pages (from-to)2207-2212
Number of pages6
JournalInternational Journal of Oncology
Volume41
Issue number6
DOIs
StatePublished - Dec 2012

Fingerprint

Inbred NOD Mouse
SCID Mice
Vincristine
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Growth
Leukemia
Diet
resveratrol
Tail
Veins
Flow Cytometry
Recurrence
Injections
Survival
Serum

Keywords

  • Acute lymphoblastic leukemia
  • Dietary resveratrol
  • NOD/SCID mice

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dietary resveratrol does not delay engraftment, sensitize to vincristine or inhibit growth of high-risk acute lymphoblastic leukemia cells in NOD/SCID mice. / Zunino, Susan J.; Storms, David H.; Newman, John W.; Pedersen, Theresa L.; Keen, Carl L; Ducore, Jonathan M.

In: International Journal of Oncology, Vol. 41, No. 6, 12.2012, p. 2207-2212.

Research output: Contribution to journalArticle

Zunino, Susan J. ; Storms, David H. ; Newman, John W. ; Pedersen, Theresa L. ; Keen, Carl L ; Ducore, Jonathan M. / Dietary resveratrol does not delay engraftment, sensitize to vincristine or inhibit growth of high-risk acute lymphoblastic leukemia cells in NOD/SCID mice. In: International Journal of Oncology. 2012 ; Vol. 41, No. 6. pp. 2207-2212.
@article{15f24246e84045619d2bee918c5ece50,
title = "Dietary resveratrol does not delay engraftment, sensitize to vincristine or inhibit growth of high-risk acute lymphoblastic leukemia cells in NOD/SCID mice",
abstract = "Acute lymphoblastic leukemia (ALL) with translocation t(4;11) is a high-risk leukemia found in 60-85{\%} of infants with ALL and is often refractory to conventional chemotherapeutics after relapse. To evaluate the efficacy of dietary resveratrol in vivo, 5-week-old NOD.CB17-Prkdcscid/J mice were fed a control diet or a diet containing 0.2{\%} w/w resveratrol. After 3 weeks of dietary treatment, mice were engrafted with the human t(4;11) ALL line SEM by tail vein injection. Engraftment was monitored by evaluating the presence of human CD19+ cells in peripheral blood using flow cytometry. Relative to control diet, dietary resveratrol did not delay the engraftment of the leukemia cells. To determine if dietary resveratrol could increase efficacy of a chemotherapeutic agent, vincristine was injected intraperitoneally into leukemic mice fed the control or supplemented diet. Survival curves and monitoring the percentage of human leukemia cells in peripheral blood showed that resveratrol did not inhibit leukemia cell growth or influence the activity of vincristine. Mass spectrometric analysis of mouse serum revealed that the majority of resveratrol was present as glucuronidated and sulfated metabolites. These data do not support the concept that dietary resveratrol has potential as a preventative agent against the growth of high-risk t(4;11) ALL.",
keywords = "Acute lymphoblastic leukemia, Dietary resveratrol, NOD/SCID mice",
author = "Zunino, {Susan J.} and Storms, {David H.} and Newman, {John W.} and Pedersen, {Theresa L.} and Keen, {Carl L} and Ducore, {Jonathan M}",
year = "2012",
month = "12",
doi = "10.3892/ijo.2012.1650",
language = "English (US)",
volume = "41",
pages = "2207--2212",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Dietary resveratrol does not delay engraftment, sensitize to vincristine or inhibit growth of high-risk acute lymphoblastic leukemia cells in NOD/SCID mice

AU - Zunino, Susan J.

AU - Storms, David H.

AU - Newman, John W.

AU - Pedersen, Theresa L.

AU - Keen, Carl L

AU - Ducore, Jonathan M

PY - 2012/12

Y1 - 2012/12

N2 - Acute lymphoblastic leukemia (ALL) with translocation t(4;11) is a high-risk leukemia found in 60-85% of infants with ALL and is often refractory to conventional chemotherapeutics after relapse. To evaluate the efficacy of dietary resveratrol in vivo, 5-week-old NOD.CB17-Prkdcscid/J mice were fed a control diet or a diet containing 0.2% w/w resveratrol. After 3 weeks of dietary treatment, mice were engrafted with the human t(4;11) ALL line SEM by tail vein injection. Engraftment was monitored by evaluating the presence of human CD19+ cells in peripheral blood using flow cytometry. Relative to control diet, dietary resveratrol did not delay the engraftment of the leukemia cells. To determine if dietary resveratrol could increase efficacy of a chemotherapeutic agent, vincristine was injected intraperitoneally into leukemic mice fed the control or supplemented diet. Survival curves and monitoring the percentage of human leukemia cells in peripheral blood showed that resveratrol did not inhibit leukemia cell growth or influence the activity of vincristine. Mass spectrometric analysis of mouse serum revealed that the majority of resveratrol was present as glucuronidated and sulfated metabolites. These data do not support the concept that dietary resveratrol has potential as a preventative agent against the growth of high-risk t(4;11) ALL.

AB - Acute lymphoblastic leukemia (ALL) with translocation t(4;11) is a high-risk leukemia found in 60-85% of infants with ALL and is often refractory to conventional chemotherapeutics after relapse. To evaluate the efficacy of dietary resveratrol in vivo, 5-week-old NOD.CB17-Prkdcscid/J mice were fed a control diet or a diet containing 0.2% w/w resveratrol. After 3 weeks of dietary treatment, mice were engrafted with the human t(4;11) ALL line SEM by tail vein injection. Engraftment was monitored by evaluating the presence of human CD19+ cells in peripheral blood using flow cytometry. Relative to control diet, dietary resveratrol did not delay the engraftment of the leukemia cells. To determine if dietary resveratrol could increase efficacy of a chemotherapeutic agent, vincristine was injected intraperitoneally into leukemic mice fed the control or supplemented diet. Survival curves and monitoring the percentage of human leukemia cells in peripheral blood showed that resveratrol did not inhibit leukemia cell growth or influence the activity of vincristine. Mass spectrometric analysis of mouse serum revealed that the majority of resveratrol was present as glucuronidated and sulfated metabolites. These data do not support the concept that dietary resveratrol has potential as a preventative agent against the growth of high-risk t(4;11) ALL.

KW - Acute lymphoblastic leukemia

KW - Dietary resveratrol

KW - NOD/SCID mice

UR - http://www.scopus.com/inward/record.url?scp=84869800973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869800973&partnerID=8YFLogxK

U2 - 10.3892/ijo.2012.1650

DO - 10.3892/ijo.2012.1650

M3 - Article

C2 - 23041950

AN - SCOPUS:84869800973

VL - 41

SP - 2207

EP - 2212

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 6

ER -